Press Release
Microvisk Technologies Exhibits at Medica 2011 exhibition in Dusseldorf
20 October 2011
Microvisk Technologies Ltd, a UK-based developer of handheld devices to monitor the blood clotting status of patients taking anti-coagulation medication will exhibit at the 4-day Medica 2011 trade show in Dusseldorf. The event, which will take place from 16-19th November at the Dusseldorf Fairgrounds, Germany is expected to be attended by leading medical device manufacturers from around the world and is internationally renowned as the premier trade show for those wishing to obtain the latest information on all current and future trends in in-patient and out-patient care. Microvisk’s exhibit can be found in Hall 2, stand B46.
Microvisk Technologies will demonstrate its revolutionary Micro Electro Mechanical Sensor (MEMS) technology specifically aimed at those suffering from blood clotting disorders and designed to enable assist such patients in receiving the correct dosage of anti-coagulation medication, such as Warfarin. Microvisk Technologies has developed the world’s first medical diagnostics strip based on a MEMS system that was originally created as a movement system for nano-robots.
Medica 2011 is the world’s largest exhibition of medical technologies and each year draws exhibitors from over 100 countries around the world ranging from global market leaders to smaller innovative players. This year, over 4,000 companies are expected to exhibit at Medica comprising of over 100,000 attendees globally. Medica is seen as essential attendance for all those involved in the healthcare industry featuring technologies from laboratory equipment and diagnostics to orthopaedic equipment and consumer goods.
John Curtis, CEO of Microvisk commented “We are delighted to be given the opportunity to exhibit at this highly acclaimed and prestigious event. We strongly believe that the exposure it will give us to the global medical devices community will benefit us enormously as our groundbreaking technology enters the next commercial phase.”
Terry Swainbank, Investment Director for Synergis Technologies, part of the Porton Capital group added “We invested in Microvisk Technologies as we believed that the Company was at the cutting edge of medical diagnostics, having developed a unique product designed to meet a clear, unmet market need. The Microvisk technology eliminates the need for a delay in sending samples to a laboratory and allows the patient to monitor their condition in the convenience and safety of their own home.”
Microvisk Technologies Ltd, a spin-out company from the Science and Technology Facilities Council, was formed in 2004 and was initially based on research carried out at the Rutherford Appleton Laboratory, Oxfordshire. Microvisk Technologies is developing a hand held Point of Care and Home Use test for patients using anti-coagulant treatments. The devices will conduct the internationally recognised Prothrombin Time test by using a drop of the patient’s whole blood taken by a finger prick. Microvisk's technology works using a different approach to the other devices and tests currently on the market, which use optical analysis or chemical reactions. Microvisk uses Micro Electro Mechanical Sensors (MEMS) on a disposable strip which incorporates a small cantilever to measure viscosity. The devices can test a small volume of whole blood making the test less intrusive and effectively removing the need for a laboratory.
- Ends -
For further information on Synergis Technologies Ltd, please contact:
Dr Dinali de Silva, Investment Executive
Tel: +44 (0) 207 932 0727
Email: dinali.desilva@synergistechnologies.com
Web: www.synergistechnologies.com
For further information on Microvisk Technologies Ltd. and all other media enquiries, please contact:
John Curtis, Chief Executive Officer
Tel: + 44 (0) 845 956 9900
Email: John.Curtis@microvisk.com
Web: www.microvisk.com
NOTES TO EDITORS
Synergis Technologies Ltd. is a privately-owned early-stage investment firm based in London providing seed capital to technology commercialisation ventures principally originating from the UK’s leading public sector research establishments and research-focused universities. Synergis, part of the Porton Capital Group identifies exciting opportunities underpinned by strong IP from spin-out companies to drive commercial exploitation and build strong management teams to execute deliverable market strategies.
Synergis seeks to take these opportunities from the laboratory to the marketplace with speed and continuity of capital, generating substantial investment returns by becoming involved very early as a proactive investor and partner. Synergis has established valuable access to this highly prized public research base and is dedicated to finding and funding a compelling pipeline of cutting-edge technologies.